The past month was rough for Amarin (AMRN) investors, to say the least. The company didn't receive a favorable ruling in their patent lawsuit against generics Dr. Reddy's (RDY) and Hikma (HKMPF ) in a U.S. District Court. Judge Miranda Du found that the generics infringed on Amarin's patents. However, she found these patents to be obvious, so they are invalid. This decision stunned me and smashed the share price down to around $4 per share. Luckily, Avisol Capital Partners published another great piece covering these legal actions and did a great job explaining the